Research Progress of Targeted Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

VernacularTitle:慢性淋巴细胞白血病/小淋巴细胞淋巴瘤靶向治疗的最新研究进展
Author: Dan CHEN ¹ ; Mei-Yi WANG ; Chen TIAN
Author Information

1. 新疆和田地区人民医院血液科,新疆和田 848000
Keywords: chronic lymphocytic leukemia; small lymphocytic lymphoma; targeted therapy
From: Journal of Experimental Hematology 2024;32(2):643-646
CountryChina
Language:Chinese
Abstract: Chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma(SLL)is a relatively inert B lymphocyte proliferative disease.In recent years with the launch of new drugs,chemotherapy has been gradually replaced by targeted therapy,which significantly prolongs the survival of patients and reduces the side effects of treatment.At present,BTK inhibitors,PI3K inhibitors,spleen tyrosine kinase(SYK)inhibitors and BCL-2 inhibitors are the most studied targeted therapeutic drugs for CLL/SLL.This article reviews the research progress of different types of targeted therapeutic drugs in the treatment of CLL/SLL.